SCOTTSDALE, Ariz.--(BUSINESS WIRE)--ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBO), today announced that preliminary results from ongoing studies in dermatological applications support Management’s goals in pursuing licensure for accelerated wound healing as well as subcutaneous immunomodulation and vaccine adjuvant activity.
